Nozaki Yuji, Kinoshita Koji, Hino Shoichi, Yano Tomohiro, Niki Kaoru, Hirooka Yasuaki, Kishimoto Kazuya, Funauchi Masanori, Matsumura Itaru
Department of Hematology and Rheumatology, Kindai University School of Medicine, Osaka, Japan
Department of Hematology and Rheumatology, Kindai University School of Medicine, Osaka, Japan.
Am J Physiol Renal Physiol. 2015 Apr 15;308(8):F899-909. doi: 10.1152/ajprenal.00362.2014. Epub 2015 Jan 28.
Nephrotoxicity is a frequent complication of cisplatin-induced chemotherapy, in which T cells are known to promote acute kidney injury (AKI). Apoptosis and necrosis of tubules and inflammatory events also contribute to the nephrotoxicity. A delineation of the mechanisms that underlie the inappropriate renal and tubular inflammation can thus provide important insights into potential therapies for cisplatin-induced AKI. Rho-kinases are known to act as molecular switches controlling several critical cellular functions, including cell migration, cytokine production, and apoptosis. Here, we show that the Rho-kinase inhibitor fasudil attenuated cisplatin nephrotoxicity, resulting in less histological damage, improved renal function, and the infiltration of fewer leukocytes into the kidney. Renal nuclear factor-κB activation and apoptosis were reduced, and the expressions of proinflammatory renal cytokine and chemokine mRNA were decreased. Urinary and renal kidney injury molecule-1 (Kim-1) expression was also reduced, a finding that is consistent with diminished kidney injury. In the current study, we also showed that fasudil could be protective of the impaired tubules. In vitro, fasudil reduced the apoptosis (annexin-V+PI cells) and cytokine production (tumor necrosis factor+ cells) in T cells and the apoptosis (annexin-V+PI cells) and tubular damage (Kim-1+ cells) in proximal tubular cells by flow cytometric analysis. As Rho-kinase plays an important role in promoting cisplatin nephrotoxicity, inhibiting Rho-kinase may be a therapeutic strategy for preventing cisplatin-induced AKI.
肾毒性是顺铂诱导化疗的常见并发症,已知T细胞会促进急性肾损伤(AKI)。肾小管的凋亡、坏死以及炎症事件也会导致肾毒性。因此,阐明不适当的肾和肾小管炎症背后的机制可为顺铂诱导的AKI的潜在治疗提供重要见解。已知Rho激酶作为分子开关控制多种关键细胞功能,包括细胞迁移、细胞因子产生和细胞凋亡。在此,我们表明Rho激酶抑制剂法舒地尔可减轻顺铂肾毒性,减少组织学损伤,改善肾功能,并减少白细胞向肾脏的浸润。肾细胞核因子-κB激活和细胞凋亡减少,促炎肾细胞因子和趋化因子mRNA的表达降低。尿和肾损伤分子-1(Kim-1)的表达也降低,这一发现与肾损伤减轻一致。在本研究中,我们还表明法舒地尔可保护受损的肾小管。在体外,通过流式细胞术分析,法舒地尔减少了T细胞中的细胞凋亡(膜联蛋白-V+PI细胞)和细胞因子产生(肿瘤坏死因子+细胞)以及近端肾小管细胞中的细胞凋亡(膜联蛋白-V+PI细胞)和肾小管损伤(Kim-1+细胞)。由于Rho激酶在促进顺铂肾毒性中起重要作用,抑制Rho激酶可能是预防顺铂诱导的AKI的一种治疗策略。